Comments and reply on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

Authors: Soto, Javier1; Holmstrom, Stefan2; Buchholz, Patricia3; Walt, John4; Wickstrøm, Jannie5; Aagren, Mark5

Source: Current Medical Research and Opinion, Volume 22, Number 10, October 2006 , pp. 1899-1902(4)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Document Type: Letter section

DOI: 10.1185/030079906X132569

Affiliations: 1: Health Outcomes Research, Medical Unit-Pfizer Spain, Avda de Europa 20-B, Parque Empresarial de la Moraleja, 28108 Alcobendas, Madrid, Spain 2: Biot, France 3: Allergan R&D Europe, Ettlingen, Germany 4: Allergan Global Health Outcomes, Irvine, CA, USA 5: MUUSMANN Research & Consulting, Copenhagen, Denmark

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A